<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095195</url>
  </required_header>
  <id_info>
    <org_study_id>IRFARPC</org_study_id>
    <nct_id>NCT04095195</nct_id>
  </id_info>
  <brief_title>Registry of Subjects at Risk of Pancreatic Cancer</brief_title>
  <acronym>IRFARPC</acronym>
  <official_title>Italian Registry of Families At Risk of Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Italiana per lo Studio del Pancreas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Italiana per lo Studio del Pancreas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing
      factors of subjects with an inherited increased risk for pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is a devastating disease with a dismal prognosis. One of the ways to
      improve survival might be early detection.

      Within years, many predisposing diseases or genetic conditions have been identified, thus
      screening/surveillance have been established worldwide.

      A registry of subjects at risk of pancreatic cancer will has been built up to investigate the
      possibility of diagnosis pancreatic cancer, or one if its predisposing lesions.

      Inclusion criteria will be adopted as &quot;enrollment criteria&quot;. According to this, individuals &gt;
      18 years old will be enrolled; their familiar history and/or genetic predisposition will be
      collected, as well as current or previous medical records/medications data. Thereafter,
      according to specific age-based criteria, those individuals initially enrolled will be will
      be considered for a &quot;surveillance protocol&quot; (&quot;interventional follow-up criteria&quot;) and they
      will be submitted to Cholangio-Wirsung Magnetic Resonance or Pancreatic Endoultrasonography
      according to the pancreatologist's prescription at each participating center.

      Individuals suffering from the following conditions will be enrolled:

      familial pancreatic cancer; Peutz-Jeghers syndrome; a known BRCA-2, BRCA-1, PALB2, or p16
      mutation with at least one first- or second-degree relative suffering from pancreatic cancer;
      hereditary pancreatitis; FAMMM syndrome; Lynch syndrome with at least one first- or
      second-degree relative suffering from pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">September 20, 2045</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2044</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>This clinical study will assess the diagnostic yield of a clinical surveillance program for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals</measure>
    <time_frame>25 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>This study will investigate possible risk factors for the incidence or the progression of for pancreatic neoplasia or predisposing conditions (PanIN, IPMNs) in high risk individuals</measure>
    <time_frame>25 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The psychological burden of a surveillance program for pancreatic cancer will be assessed</measure>
    <time_frame>10 years</time_frame>
  </other_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Familial Pancreatic Cancer</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Lynch Syndrome</condition>
  <condition>FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome</condition>
  <condition>Hereditary Pancreatitis</condition>
  <condition>Peutz-Jeghers Syndrome</condition>
  <arm_group>
    <arm_group_label>Familial pancreatic cancer relatives</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Peutz-Jeghers syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>BRCA 1/2, PALB2, p16 mutations with familiarity for PC</arm_group_label>
    <description>Known genetic mutation and at least 1 1st- or 2nd-degree relative suffering from PC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lynch syndrome with familiarity for pancreatic cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>FAMMM syndrome</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary and genetic pancreatitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MRCP</intervention_name>
    <description>Subjects fulfilling the &quot;radiological follow-up criteria&quot; will be submitted to MRCP or EUS according to the pancreatologist's prescription</description>
    <arm_group_label>BRCA 1/2, PALB2, p16 mutations with familiarity for PC</arm_group_label>
    <arm_group_label>FAMMM syndrome</arm_group_label>
    <arm_group_label>Familial pancreatic cancer relatives</arm_group_label>
    <arm_group_label>Hereditary and genetic pancreatitis</arm_group_label>
    <arm_group_label>Lynch syndrome with familiarity for pancreatic cancer</arm_group_label>
    <arm_group_label>Peutz-Jeghers syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoultrasonography</intervention_name>
    <description>Subjects fulfilling the &quot;radiological follow-up criteria&quot; will be submitted to MRCP or EUS according to the pancreatologist's prescription</description>
    <arm_group_label>BRCA 1/2, PALB2, p16 mutations with familiarity for PC</arm_group_label>
    <arm_group_label>FAMMM syndrome</arm_group_label>
    <arm_group_label>Familial pancreatic cancer relatives</arm_group_label>
    <arm_group_label>Hereditary and genetic pancreatitis</arm_group_label>
    <arm_group_label>Lynch syndrome with familiarity for pancreatic cancer</arm_group_label>
    <arm_group_label>Peutz-Jeghers syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects at high-risk of pancreatic cancer will be enrolled and a surveillance examination
        will be performed according to inclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria to enter the registry:

          -  individuals with at least two relatives suffering from pancreatic cancer, with at
             least 1 first-degree and until the third-degree

          -  subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1
             first- or 2nd-degree relative suffering from pancreatic cancer

          -  subjects suffering from FAMMM Syndrome

          -  subjects suffering from Peutz-Jeghers Syndrome

          -  subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis

          -  subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative
             suffering from pancreatic cancer

        Inclusion criteria to join the &quot;radiologic follow-up&quot;:

          -  45 years or 10 years younger than the youngest index case of pancreatic cancer in the
             family for familial cases

          -  40 years or 5 years younger than the youngest index case of pancreatic cancer for
             subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a
             known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer

          -  30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome

        Exclusion Criteria:

        - pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Salvatore Paiella, MD, PhD</last_name>
    <phone>00390458126009</phone>
    <email>salvatore.paiella@univr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Carrara, MD</last_name>
    <phone>+ 39 02 82247288</phone>
    <email>silvia.carrara@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Carrara, MD</last_name>
      <email>silvia.carrara@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Zerbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luigi Laghi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Poliani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentina Giatti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pederzoli</name>
      <address>
        <city>Peschiera Del Garda</city>
        <state>Verona</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Butturini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Giardino, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabella Frigerio, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffele Vita Salute University Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Falconi, MD</last_name>
      <email>massimo.falconi@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Gabriele Capurso, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Smaniotto</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia Generale e del Pancreas</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Paiella, MD, PhD</last_name>
      <phone>00390458126009</phone>
      <email>salvatore.paiella@univr.it</email>
    </contact>
    <contact_backup>
      <last_name>Erica Secchettin, PharmD</last_name>
      <phone>00390458126254</phone>
      <email>erica.secchettin@univr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Salvatore Paiella, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Malleo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Bassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Salvia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Secchettin, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Marinelli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.aisponline.it/index.php?page=1296&amp;lang=ITA</url>
    <description>Website of the Association, link to the webpage of the registry</description>
  </link>
  <results_reference>
    <citation>Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, Signoretti M, Crippa S, Carrara S, Frigerio I, Bassi C, Falconi M, Iannicelli E, Giardino A, Mannucci A, Laghi A, Laghi L, Frulloni L, Zerbi A. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. Am J Gastroenterol. 2019 Apr;114(4):665-670. doi: 10.1038/s41395-018-0414-z.</citation>
    <PMID>30538291</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial Pancreatic Cancer</keyword>
  <keyword>BRCA Mutation</keyword>
  <keyword>Lynch Syndrome</keyword>
  <keyword>Screening pancreatic cancer</keyword>
  <keyword>Surveillance pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Peutz-Jeghers Syndrome</mesh_term>
    <mesh_term>Dysplastic Nevus Syndrome</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

